Sarhad University of Sciences and Information Technology, Pakistan
Posters & Accepted Abstracts: Virol-mycol
Due to the high rate of asymptomatic infections an advanced screening assay is of prompt importance to be used for the clinical diagnosis of HCV. Early detection of anti HCV is the first step in the management of chronic hepatitis and in the selection of patients needing treatments. The frequent methods used for the diagnosis of HCV infection based on the detection of anti HCV antibodies in the serum or plasma but nevertheless the concentration of these antibodies reaches to detectable level after a long window period of HCV infection. Various methods are implemented for the diagnosis of hepatitis infection i.e., Immune Chromatographic Technique (ICT), Enzyme Linked Immunosorbent Assay (ELISA) and HCV-RNA by PCR, but due to the false positivity rate of HCV with ICT based methods, ELISA is considered to be more consistent than ICT based HCV. Chemiluminescent Microparticle Immunoassay is the modified and advanced form of the Enzyme Linked Immunosorbent Assay (ELISA) technique. Architect system is designed to detect antibodies to putative structural and non structural protein (HCr-43, c-100, NS3, NS4) of HCV genome. According to the CDC all the screening methods used for the detection of anti HCV need supplementary methods like HCV RNA or nucleic acid testing (NAT) for their further confirmation.